Evaluation of the anti-Toxoplasma gondii Activity of Hederagenin in vitro and in vivo

Korean J Parasitol. 2021 Jun;59(3):297-301. doi: 10.3347/kjp.2021.59.3.297. Epub 2021 Jun 21.

Abstract

Toxoplasma gondii infection is widespread worldwide, not only posing a serious threat to human food safety and animal husbandry, but also endangering human health. The selectivity index was employed to measure anti-T. gondii activity. Hederagenin (HE) exhibited potent anti-T. gondii activity and low cytotoxicity. For this reason, HE was selected for in vivo experiments. HE showed 64.8%±13.1% inhibition for peritoneal tachyzoites in mice, higher than spiramycin 56.8%±6.0%. Biochemical parameters such as alanine aminotransferase, aspartate aminotransferase, glutathione, and malondialdehyde, illustrated that HE was a good inhibitor of T. gondii in vivo. This compound was also effective in relieving T. gondii-induced liver damage. Collectively, it was demonstrated that HE had potential as an anti-T. gondii agent.

Keywords: Toxoplasma gondii; hederagenin; in vitro; in vivo; inhibition.

MeSH terms

  • Animals
  • Aspartate Aminotransferases
  • Mice
  • Oleanolic Acid* / analogs & derivatives
  • Toxoplasma*
  • Toxoplasmosis* / drug therapy

Substances

  • Oleanolic Acid
  • Aspartate Aminotransferases
  • hederagenin